A large analysis presented at Kidney Week and published in JAMA found sodium‑glucose cotransporter‑2 (SGLT2) inhibitors improve kidney outcomes across a wide range of glomerular filtration rates and albuminuria levels, including non‑diabetic patients. The pooled evidence shows consistent reductions in kidney‑related events and hospitalizations regardless of baseline renal function or urinary protein. A complementary analysis quantified heterogeneous treatment effects by diabetes status and albuminuria, reinforcing broad applicability of SGLT2s in nephrology practice. Investigators recommended expanding guideline recommendations and payer coverage to reflect the class’s cross‑population efficacy.